Intech Biopharm Ltd Asset Resilience Ratio

Latest as of March 2026: 6.12%

Intech Biopharm Ltd asset resilience ratio. Intech Biopharm Ltd (6461) has an Asset Resilience Ratio of 6.12% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6461 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

NT$142.50 Million

≈ $4.49 Million USD Cash + Short-term Investments

Total Assets

NT$2.33 Billion

≈ $73.33 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Intech Biopharm Ltd (2019–2025)

Asset resilience ratio of Intech Biopharm Ltd from 2019 to 2025. This chart shows how Intech Biopharm Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Intech Biopharm Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Intech Biopharm Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 6461 total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$142.50 Million	6.12%
Total Liquid Assets	NT$142.50 Million	6.12%

Asset Resilience Insights

Limited Liquidity: Intech Biopharm Ltd maintains only 6.12% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Intech Biopharm Ltd Industry Peers by Asset Resilience Ratio

Compare Intech Biopharm Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Intech Biopharm Ltd Asset Resilience Ratio by Year (2019–2025)

Intech Biopharm Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Intech Biopharm Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	8.40%	NT$197.50 Million ≈ $6.22 Million	NT$2.35 Billion ≈ $74.07 Million	+5.90pp
2024-12-31	2.51%	NT$60.02 Million ≈ $1.89 Million	NT$2.40 Billion ≈ $75.48 Million	-16.69pp
2023-12-31	19.20%	NT$520.40 Million ≈ $16.40 Million	NT$2.71 Billion ≈ $85.41 Million	+7.04pp
2022-12-31	12.16%	NT$310.12 Million ≈ $9.77 Million	NT$2.55 Billion ≈ $80.35 Million	+7.74pp
2021-12-31	4.42%	NT$115.00 Million ≈ $3.62 Million	NT$2.60 Billion ≈ $81.97 Million	+0.61pp
2020-12-31	3.81%	NT$100.00 Million ≈ $3.15 Million	NT$2.62 Billion ≈ $82.59 Million	-0.22pp
2019-12-31	4.03%	NT$105.00 Million ≈ $3.31 Million	NT$2.61 Billion ≈ $82.09 Million	--

pp = percentage points

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$95.93 Million

NT$3.04 Billion TWD

Market Cap Rank

#19182 Global

#1080 in Taiwan

Share Price

NT$27.60

Change (1 day)

+1.47%

52-Week Range

NT$14.40 - NT$29.20

All Time High

NT$57.64